Cellebrite DI Ltd. Investigation - CLBT

Company
Cellebrite DI Ltd. (NASDAQ: CLBT)

Learn more about the Cellebrite DI Ltd. Investigation

Required Field

Required Field

Required Field

  • $1 - $1,000
  • $1001 - $10,000
  • $10,001 - $25,000
  • $25,001 - $50,000
  • $50,001 - $100,000
  • $100,001 - $250,000
  • $250,001 - $500,000
  • $500,000+

There is no cost or obligation for you to submit.

The submission of this form does not create an attorney-client relationship.

Please Upload related files below

Add Transactions

Purchases

1.
  • Common Stock
  • Preferred Stock
  • Bonds
  • Calls
  • Puts
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12

Additional Purchases

Sales

1.
  • Common Stock
  • Preferred Stock
  • Bonds
  • Calls
  • Puts
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12

Additional Sales

Please input at least 1 transaction or press "skip for now" button below

Please fill in all the fields for your transaction or press "skip for now" button below

Alternatively, you may upload your transactions below or e-mail them to [email protected]

Upload Your Stock Tickers

Tell us the stocks you own using SnapTrade, and we will keep you informed about class action litigation related to your stocks. We monitor critical case developments that may affect the price of your shares and your possible monetary recovery. SnapTrade only shares the tickers you own and your transaction history, not your account numbers. Using SnapTrade and participating in our monitoring service is free and does not create any attorney-client relationship or obligation on your part.

Don’t miss out on possible monetary recovery - link your brokerage account with SnapTrade.

Skip

Cellebrite DI Ltd. Investigation Details

Cellebrite DI Ltd. shareholders lost money in August 2026 when the stock fell sharply after the Company reported Q2 2026 financial results that missed revenue expectations, lowered full-year ARR and revenue guidance, and announced a CEO transition. Management conceded they "did not deliver the ARR and revenue performance they expected in the second quarter." Notably, the Company reported ARR of $507.8 million, below the $510-$513 million range provided last quarter. Q2 revenue of approximately $131.1 million also came in below analyst consensus. Despite previous claims in February, 2026, of being "well positioned to reaccelerate growth," Cellebrite ultimately slashed its projected ARR growth rate for fiscal 2026 to 14%-16%, down from the 18%-19% target reaffirmed just last quarter. Management pointed to a "meaningful acceleration" in Q2 that never manifested and several large transactions that were delayed. The investigation concerns whether Cellebrite DI Ltd. adequately disclosed the risks inherent in its prior projections ahead of its Q2 2026 earnings report.

Get Started